Hostname: page-component-78c5997874-xbtfd Total loading time: 0 Render date: 2024-11-07T09:51:09.186Z Has data issue: false hasContentIssue false
  • English
  • Français

Tolerability of intranasal esketamine, a case series of 15 patients

Published online by Cambridge University Press:  27 August 2024

I. Álvarez Correa ,
C. Delgado Marmisa ,
H. J. Vizcaíno Herrezuelo ,
L. Egüen Recuero ,
E. Garrido Dobrito ,
L. D. Téllez de Cepeda ,
L. Gayubo Moreo ,
B. Sanz-Aránguez Ávila ,
L. Caballero Martínez  and
R. de Arce Cordón
I. Álvarez Correa
Affiliation:
1M.I.R. Psiquiatría
C. Delgado Marmisa
Affiliation:
1M.I.R. Psiquiatría
H. J. Vizcaíno Herrezuelo
Affiliation:
1M.I.R. Psiquiatría
L. Egüen Recuero
Affiliation:
2Enfermería Psiquiatría
E. Garrido Dobrito
Affiliation:
2Enfermería Psiquiatría
L. D. Téllez de Cepeda
Affiliation:
3F.E.A Farmacología Clínica
L. Gayubo Moreo*
Affiliation:
4F.E.A Psiquiatría
B. Sanz-Aránguez Ávila
Affiliation:
4F.E.A Psiquiatría
L. Caballero Martínez
Affiliation:
5Jefe de Sección Psiquiatría
R. de Arce Cordón
Affiliation:
6Jefa de Servicio Psiquiatría, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Intranasal esketamine has recently been approved for the treatment of treatment-resistant depression in adults, with different studies showing its efficacy and tolerability. However, the real-world tolerability of this treatment is still unclear.

Objectives

Evaluate the tolerability of intranasal esketamine in a case series of 15 patients.

Methods

Our case series includes 15 patients, who received treatment with intranasal esketamine during 2022-2023. In order to evaluate the tolerability of intranasal esketamine, patients were asked to complete the TSQM and a side effect questionnaire on different moments of the treatment (one week, six weeks and six months after the beginning of the treatment).

Results

The most common adverse effects were dissociation, dizziness, and somnolence, which resolved within the hours following the administration. All of them were mild or moderate in severity, having a minor impact on the patient, so none of the patients discontinued the treatment due to adverse effects. Other adverse effects noticed were: transitory increment of blood pressure in several patients, and worsening of obsessions in a patient with previous obsessive-compulsive symptoms.

Conclusions

Our data suggests that intranasal esketamine is well tolerated, with transient and mild adverse effects. In all cases the risk-benefit ratio must be evaluated, but until more studies are done, it seems to be a safe treatment for treatment-resistant depression.

Disclosure of Interest

None Declared

Type
Abstract
Information
European Psychiatry , Volume 67 , Special Issue S1: Abstracts of the 32nd European Congress of Psychiatry , April 2024 , pp. S543
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2024. Published by Cambridge University Press on behalf of European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.